EODData

MEMBERSHIP REGISTER LOG IN

FRA, 8CC: COCRYSTAL PHARMA NEW O.N.

07 Nov 2025
LAST:

0.8500

CHANGE:
 0.03		OPEN:
0.8500		HIGH:
0.8500		ASK:
0.0000		VOLUME:
2.2K
CHG(%):
2.86		PREV:
0.8750		LOW:
0.8500		BID:
0.0000		 

CHART

RECENT END OF DAY PRICES

DateOpenHighLowCloseVolume
07 Nov 250.85000.85000.85000.85002.2K
06 Nov 250.87500.87500.87500.87502.2K
05 Nov 250.87000.87000.87000.87002.2K
04 Nov 250.91000.95000.91000.95002.2K
03 Nov 250.91500.91500.91500.91502.9K
31 Oct 250.92000.92000.92000.92002.9K
30 Oct 250.97000.97000.97000.97002.9K
29 Oct 251.03001.03001.03001.03002.9K
28 Oct 251.09001.09001.09001.09002.9K
27 Oct 250.99000.99000.99000.99002.9K

COMPANY PROFILE

Name:COCRYSTAL PHARMA NEW O.N.
About:Cocrystal Pharma, Inc., a biotechnology company, focuses on the discovery and development of antiviral therapeutic treatments for serious and/or chronic viral diseases in the United States. It employs structure-based technologies to create antiviral drugs including influenza virus, coronaviruses, such as SARS-CoV-2 and MERS-CoV, as well as norovirus, respiratory virus infections, and hepatitis C virus (HCV) infections. The company develops CC-42344, a novel PB2 inhibitor, which is in phase 2a clinical trial, as a potential treatment for pandemic and seasonal influenza A; and the inhaled CC-42344 for the potential prophylactic treatment of pandemic and seasonal influenza infections. It is also developing CDI-988, an oral pan-viral, which is phase 1 clinical trial to treat noroviruses and coronaviruses, including SARS-CoV-2 and its variants; and CC-31244, a HCV non-nucleoside inhibitor that has completed Phase 2a clinical trial to treat HCV. The company has a license and research collaboration agreement with Merck Sharp & Dohme Corp. to discover and develop proprietary influenza A/B antiviral agents; and a license agreement with Kansas State University Research Foundation to develop antiviral compounds for the treatment of norovirus and coronavirus infections. Cocrystal Pharma, Inc. was founded in 2006 and is based in Bothell, Washington.
Sector:Healthcare
Industry:Biotechnology
Address:19805 North Creek Parkway, Bothell, WA, United States, 98011
Website:https://www.cocrystalpharma.com
ISIN:US19188J4094

API SERVICE  NEW

Have you tried our new API Service yet?

For more information, visit our API page.

You can get your ApiKey over HERE.

If you're ready to get going, then jump over to:
https://api.eoddata.com

SYMBOL HISTORY

   Add to Watchlist

DOWNLOAD DATA

Download stock quote history quickly and easily in a variety of formats to suit your needs.

  Download

FUNDAMENTALS

Trailing P/E:-0.55 
PEG Ratio:0.01 
Price to Book:1.74 
Return on Assets:-0.53 
Return on Equity:-1.11 
Shares:10.26M 
Market Cap:8.72M 

TECHNICAL INDICATORS

MA5:0.894.9%
MA10:0.9511.3%
MA20:0.939.0%
MA50:1.0624.7%
MA100:1.2243.2%
MA200:1.3457.8%
RSI14:42.28
WPR14:-100.00 
MTM14:-0.07
ROC14:-0.07 
ATR:0.04 
Week High:0.9511.8%
Week Low:0.850.0%
Month High:1.0928.2%
Month Low:0.8557.8%
Year High:2.88238.2%
Year Low:0.850.0%

RECENT SPLITS

Date Ratio
11 Oct 20221-12